OBJECTIVE: There is an increased incidence of renal glomerulosclerosis in obese individuals. One of the major structural changes observed in nephropathy is the increase in kidney size, which may occur due to hypertrophy or changes in the rate of hyperplasia or apoptosis. Here we investigated whether leptin, the product of the obese (ob) gene which is found at high plasma levels in obese and diabetic individuals, alters any of these parameters. RESULTS: We show that leptin increased hypertrophy of these cells. This was indicated by an approximately 33% increase in cell size and 40% increase in leucine incorporation. Furthermore, we show that the hypertrophic effect of leptin was mediated via PI 3-kinase and ERK1/2 by using the inhibitors LY294002 and PD98059, respectively. We also confirm that leptin activates both PI 3-kinase and ERK1/2 in these cells. We show that hyperplasia was not affected by leptin by measuring rat glomerular mesangial cell number and by assessing bromodeoxyuridine uptake. Leptin also did not alter caspase 3-like activity under control conditions or upon induction of apoptosis by ultraviolet light, suggesting that apoptosis was not regulated by leptin in these cells. CONCLUSION: Our results show that leptin induced glomerular mesangial cell hypertrophy via PI 3-kinase and ERK1/2, and that hyperplasia and apoptosis were not altered by leptin. The hypertrophic effect of leptin may play a role in the pathophysiology of nephropathy associated with obesity.
Introduction
There is a clear association between obesity and compromised renal function, 1 ,2 yet the mechanisms underlying this association are unclear. Obesity causes many structural and functional alterations, and increased kidney size resulting mainly from mesangial cell hypertrophy and extracellular matrix accumulation leading to basement membrane thickening are the earliest morphological abnormalities to occur in nephropathy. 3 These manifest as increased glomerular filtration rate, increased renal blood flow, and ultimately can lead to kidney failure. 4, 5 Consequently, kidney function is compromised and renal failure may ultimately ensue. The mechanisms underlying many of the structural changes observed in obesity-induced nephropathy have still not been fully elucidated. One potential mechanism involves the fact that obesity is a major risk factor for the development of insulin resistance and therefore type 2 diabetes, and it is well established that hyperglycemia causes many of the changes commonly seen in nephropathy. 2 Direct effects of adipose-derived factors (adipokines) whose circulating levels are altered in obesity is another potential cause of kidney damage. Circulating levels of leptin, the product of the obese (ob) gene, show a positive correlation with body mass index. 6 The important role of leptin in maintaining body weight, food intake and energy expenditure has been well documented. 7 Recent work has shown that the physiological effects of leptin are mediated via a family of leptin receptors (ob.R) located not only in the central nervous system but also in many peripheral tissues. 8, 9 However, the importance of leptin in regulation of kidney function is only now becoming clear. [10] [11] [12] Leptin has been previously demonstrated to function as a growth factor for the kidney in a study showing leptinstimulated proliferation of glomerular endothelial cells. 13 Treatment of glomerular endothelial cells with leptin (6.25-625 nM) led to a significant increase in cell proliferation, as measured by 3 [H]thymidine incorporation into DNA and direct cell counting at 24-96 h of treatment. 13 In glomerular endothelial cells, leptin has also been shown to stimulate mRNA expression of transforming growth factor (TGF)-b1 and type IV collagen synthesis. 13 Conversely, leptin stimulated type I collagen synthesis in mesangial cells and did not alter proliferation. 13 Leptin has also been shown to regulate apoptosis in many cell types. For example, leptin treatment of human bone marrow stromal cells (hBMSC) increased the rate of cell death. 14 On the other hand, leptin protected against retinoic acid-induced apoptosis in human osteoblasts. 15 In this study, we hypothesized that high levels of leptin found in human obesity might be an important factor mediating the changes leading to kidney disease. Specifically, we investigated whether leptin may contribute to the increase in kidney size by regulating glomerular mesangial cell proliferation, hypertrophy or apoptosis.
Materials and methods

Materials
A stable population of rat glomerular mesangial cells was kindly provided by Dr George Fantus, University of Toronto, Canada. Recombinant murine leptin was purchased from Calbiochem (San Diego, CA, USA). Bio-Rad protein assay kit was from Bio-Rad Laboratories (Burlington, Canada). The bromodeoxyuridine (BrdU) assay kit was from Oncogene Research Products (San Diego, CA, USA). The CPP32/caspase-3 colorimetric assay kit was obtained from Medical & Biological Laboratories Co. (Nagoya, Japan). Enhanced chemiluminescent (ECL) detection system and [ 3 H]leucine were purchased from Amersham (Quebec, Canada). Antiphosphotyrosine antibody (PY-99) and PI 3-kinase p85 antibody (Z-8) were purchased from Santa Cruz Biotech (Santa Cruz, CA, USA). Phospho-ERK antibody and HRP-linked secondary antibodies were from Cell Signaling (Beverley, MA, USA). All other chemicals were of the highest grade available.
Cell culture Glomerular mesangial cells were routinely cultured in Dulbecco's modified Eagle's medium (DMEM) containing 5.6 mM glucose that was supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. The cells were grown at 371C in 5% CO 2 . At approximately 70% confluence, cells were subcultured in fresh DMEM.
Measurement of cell number
Glomerular mesangial cells were seeded in a 24-well plate in 0.5% serum-containing medium. Each experiment was carried out by having two sets of control cells; time zero (Con (t ¼ 0)) and cells grown for 24 h (Con (t ¼ 24)). Control cells (Con (t ¼ 24 h)) were allowed to grow for 24 h and in parallel a set of cells were treated with 60 nM leptin for 24 h. Cells were washed with PBS and then trypsinized with 0.5 ml of 0.25% trypsin (0.1% EDTA). An aliquot of the trypsinized cell suspension was diluted 1 : 1 in trypan blue dye to identify nonviable cells. Cells were counted in a doubleblind manner using a hemocytometer as previously described by us. 16, 17 BrdU incorporation assay BrdU incorporation was conducted as described previously, 17 using a kit from Oncogene Research Products as per the manufacturers' instructions. Briefly, glomerular mesangial cells were seeded in a 96-well plate at a concentration of 1-2 Â 10 5 cells/ml. After 24 h incubation, cells were treated with or without 60 nM leptin. Both control-and leptintreated cells were incubated with the 10 mM BrdU label for 24 h at 371C. After the 24 h incubation, the BrdU label was removed and cells were fixed and denatured. Each well was then incubated with monoclonal anti-BrdU antibody and incubated for 1 h at room temperature. The wells were washed with 1 Â wash buffer and incubated with peroxidase goat anti-mouse IgG HRP conjugate for 30 min at room temperature. The absorbance of product formed in each well was measured at dual wavelengths of 450-540 nm using a spectrophotometric plate reader.
Measurement of cell size
Glomerular mesangial cells were seeded in DMEM containing 0.5%. FBS on six-well plates at B40% confluency. Cells were allowed to grow for 2 h before being treated with 60 nM leptin for 24 h and/or inhibitors LY294002 (25 mM) and PD98059 (25 mM). Cells were then rinsed with PBS and fixed with 3% paraformaldehyde on ice for 5 min. The area of individual cells was measured by obtaining images using an Olympus FluoView confocal microscope and subsequently using FluoView software to quantitate data.
Measurement of [
3 H]leucine incorporation Glomerular mesangial cells grown in 24-well plates were serum-starved for 24 h, then stimulated with or without 60 nM leptin for 24 h. The cells were then pulsed with 0.5 mCi/ml [ Western blot analysis of MAP kinase (ERK1/2) phosphorylation Cells were grown on six-well plates and, after treatment with or without leptin as indicated, were then washed twice with ice-cold PBS. Subsequently, as we previously described, 18 cells were lysed in 1x SDS sample buffer (62.5 mM Tris-HCI, pH 6.8, 2% w/v SDS, 10% glycerol, 50 mM DTT, 0.01% w/v bromophenol blue) and protease and phosphatase inhibitors (1 mM Na 3 VO4, 1 mM leupeptin, 1 mM pepstatin, 1 mM okadaic acid, and 1 mM PMSF), passed through a syringe several times and heated (651C, 5 min). Cell lysates were then centrifuged for 5 min in a benchtop microfuge (13 000 rpm) and approximately 50 mg (30 ml) protein was resolved by 10% SDS-PAGE, then immunoblotted onto a PVDF membrane. The gels were stained in 0.5% Coomassie Blue stain to check for equal protein loading. Membranes were blocked with 3% BSA dissolved in 1 Â wash buffer solution of 50 mM TrisBase, 150 mM NaCI, 1% Triton-X-100 and 1% NP-40 for 2-3 h. Membranes were incubated overnight with phosphospecific ERK1/2 antibody (1 : 500) at 41C. Membranes were then washed four times in 1 Â wash buffer for 15 min each at room temperature. Washed membranes were then incubated with HRP-coupled goat anti-rabbit secondary (1 : 10 000) for 1 h. Membranes were washed five times in 1 Â wash buffer for 10 min each and phosphorylated ERK visualized using ECL and quantified using the Scion Image program.
PI 3-kinase regulatory subunit association with phosphotyrosine immunoprecipitates Cells were grown on siz-well plates to prepare immunoprecipitates then lysed with 0.75 ml. lysis buffer (50 mM HEPES, pH 7.6, 150 mM NaCI, 10% glycerol (vol/vol), 1% Triton X-100 (vol/vol), 30 mM sodium pyrophosphate, 10 mM NaF and 1 mM EDTA) supplemented with 1 mM Na 2 VO4 and protease inhibitors (10 mM E-64, 1 mM pepstatin A, 1 mM leupeptin and 0.2 mM PMSF) as described previously. 17 Phosphotyrosine-containing proteins were immunoprecipitated by incubating lysates overnight with 2 mg of antiphosphotyrosine antibody (PY99, Santa Cruz) per sample. Protein-A Sepharose beads (25 ml of a 100 mg/ml slurry) were then added for 1 h to precipitate the immunocomplexes. Immunoprecipitates were washed three times with PBS containing 1% NP-40 (vol/vol) and 1 mM Na 2 VO 4 , then 35 ml of 2Â Laemmli sample buffer was added and immunoprecipitated proteins resolved by 10% SDS-PAGE, and then immunoblotted onto PVDF membrane. Subsequently, membranes were treated as described above, but incubated overnight with anti-p85 antibody (1 : 500 Santa Cruz Biotechnology, Rabbit polyclonal) and HRP-coupled goat anti-rabbit secondary (1 : 10 000).
Caspase-3/CPP32 apoptosis assay Cells were seeded in a 12-well plate and were allowed to attach for 2 h. The cells were then serum-starved for 2 h before exposing them to ultraviolet radiation for 15 min to induce apoptosis as described previously. 16 Cells were then treated with or without 60 nM leptin and incubated for 22 h at 371C. Cells were counted using a hemocytometer and 1.5 Â 10 6 cells were resuspended in 50 ml of chilled cell lysis buffer and incubated on ice for 10 min. The cell suspension was centrifuged at 10 000 g for 1 min. The supernatant was assayed by using 100 mg protein, adding 50 ml of 2 Â reaction buffer, followed by the addition of 5 ml of 4 mM DEVD-pNA substrate and incubated at 371C for 2 h. Sample reading was taken with a spectrophotometer at 405 nm.
Statistical analysis
Data analysis was completed by two-way analysis of variance (ANOVA) with Tukey-Kramer multiple comparison test. The level of significance was set at Po0.05.
Results
Leptin did not induce glomerular mesangial cell proliferation measured by direct cell counting and BrdU incorporation assay To assess the effect of leptin on the rate of glomerular mesangial cell proliferation, cells were counted with a hemocytometer. Cells treated with 60 nM leptin for 24 h did not demonstrate any difference in cell number in comparison to control cells (Figure 1 ). The trypan blue dye exclusion method ensured that only viable cells were counted. Although counted in a double-blind manner, since cells were counted manually, we believed it was advisable to use another method for determining cell proliferation. We chose the 5 0 -bromo-2 0 -deoxyuridine (BrdU) incorporation assay, which measures newly synthesized DNA as another index of cell proliferation. Leptin induces mesangial cell hypertrophy MP-S Lee et al substituting for thymidine. DNA synthesis in glomerular mesangial cells was detected by using an anti-BrdU antibody, which binds to incorporated BrdU, followed by addition of horseradish peroxidase-conjugated goat anti-mouse antibody. Again, the amount of BrdU incorporation in leptintreated glomerular mesangial cells was not significantly different from that in control cells (Figure 2) . Therefore, these results demonstrated that leptin does not increase glomerular mesangial cell hyperplasia.
Leptin-induced hypertrophy measured by an increase in glomerular mesangial cell size and [
H]leucine incorporation
Having shown that leptin did not effect glomerular mesangial cell hyperplasia, we then investigated whether leptin could regulate hypertrophy. The areas of control-and leptintreated cells were measured by imaging cells and then quantitating cell size using Fluo View software. As shown in Figure 3 , leptin induced an approximately 33% increase in cell size compared to control cells. We then investigated the signaling pathway by which leptin increased cell size. For this, we used specific inhibitors of kinases, which, based on published literature, were likely to mediate this effect of leptin. 9 As shown in Figure 3 , in the presence of both LY294002 and PD98059, leptin induced cell size was significantly reduced, suggesting a role for PI 3-kinase and ERK1/2. We also investigated the effects of leptin on [ (Figure 4) . Together, these data suggest that leptin induces glomerular mesangial cell hypertrophy via a signaling pathway involving PI 3-kinase and ERK1/2.
Leptin activates PI 3-kinase and ERK1/2 MAPKs in glomerular mesangial cells
Having used pharmacological inhibitors which suggest that leptin increased hypertrophy via PI 3-kinase and ERK1/2, it was then important to demonstrate that leptin activated the kinases targeted by these inhibitors in glomerular mesangial cells. First, we measured ERK1/2 MAPK phosphorylation and as shown in Figure 5a , dual phosphorylation of ERK1/2 was apparent at 5 and 10 min of leptin treatment. Leptin also induced the activation of PI-3 kinase in glomerular mesangial cells. Treatment with leptin for 5 and 10 min showed an increase in association of the regulatory p85 subunit of PI 3-kinase with phosphotyrosine immunoprecipitates (Figure 5b ). Glomerular mesangial cell apoptosis was not affected by leptin Cell apoptosis was measured by determining caspase 3-like activity. Caspase activity measurement showed no change in basal levels in control-and leptin-treated cells. In cells exposed for 15 min to UV light to induce apoptosis, there was a 38% increase in caspase-3 activity, which was also Leptin induces mesangial cell hypertrophy MP-S Lee et al unaffected by pretreatment with leptin ( Figure 6 ). This indicated that leptin does not alter basal or UV-induced apoptosis in glomerular mesangial cells.
Discussion
In some obese individuals, nephropathy may result due to the development of insulin resistance and therefore hyperglycemia, a well-characterized cause of changes in kidney structure and function. 3, 20 We believe that adipokines such as leptin, whose circulating levels are altered in obese individuals, may regulate kidney function both via centrally mediated effects such as stimulation of sympathetic outflow or via direct effects on the kidney. 10, 12 Here we studied the latter by examining the effect of leptin on mesangial cell proliferation, apoptosis and hypertrophy. The rationale for examining these effects is that an increase in size is characteristic of kidney damage. This may occur due to an increase in the rate of cell proliferation and also hypertrophy of existing cells. [3] [4] [5] Previous studies have shown that leptin can regulate several aspects of kidney function. It has been shown that leptin may act directly as a renal growth and fibrogenic factor, stimulating proliferation of glomerular endothelial cells and collagen production in mesangial cells. 13, 21 The fact that the latter effect occurred in db/db mouse mesangial cells, which lack the functional long form of the leptin receptor (ob.R L ), and that abundant short leptin receptor isoform (ob.R s ) is detected in abundance in kidney tissue 22 suggests that the direct effects of leptin on the kidney are mediated via ob.R s . Leptin has also been shown to directly increase diuresis and natriuresis without altering blood pressure or potassium excretion. 23, 24 Leptin may also stimulate renal sympathetic nerve activity and thus control tubular sodium reabsorption. 25, 26 The leptin-induced development of insulin resistance in obese individuals. 27 is another mechanism whereby kidney function can be altered by leptin. Each of the molecular alterations which could lead to a change in overall size of the kidney was investigated here. An increase in overall kidney size could result from increased Leptin induces mesangial cell hypertrophy MP-S Lee et al proliferation or decreased apoptosis, and therefore an overall increase in cell number or an increase in the size of existing cells. We first examined the effect of leptin on the latter and found an increase in glomerular mesangial cell hypertrophy in response to leptin. This was first observed as an increase in cell size by microscopic analysis. We confirmed a hypertrophic effect, as opposed to simply passive cell swelling, by demonstrating that leptin increased leucine incorporation in these cells, indicative of increased protein synthesis. Hypertrophy has been well characterized as an important pathophysiological feature of nephropathy, for example, being induced in diabetes by hyperglycemia, and this occurs through a MAP kinase-dependent mechanism. 20 Indeed, MAP kinase and PI 3-kinase signaling pathways have been shown to be important regulators of mesangial cell hypertrophy 28, 29 and leptin has been shown to regulate both of these kinases in a variety of cell types.
9,17
Here we confirm that leptin ativates both ERK1/2 and PI 3-kinase in glomerular mesangial cells, and we used specific inhibitors of each kinase to demonstrate that inhibition of ERK1/2 or PI 3-kinase signaling attenuated leptin-induced hypertrophy.
In the progression of glomerular disease, the total cell number is regulated by a balance between cell proliferation and apoptosis. Proliferation of mesangial cells represents an important response to stress or injury, but, if uncontrolled, can contribute significantly to an increase in kidney size and ultimately compromise renal function. Here we found no change in mesangial cell hyperplasia, which suggests that leptin cannot impact the development of nephropathy in this way. Notably, the change in mesangial endothelial cell hyperplasia seen by others 13 may be associated with other effects of leptin, such as angiogenesis. Apoptosis of mesangial cells is an important mechanism in the maintenance of glomerular homeostasis and the development of renal disease. For example, apoptosis may be required to alleviate the development of glomerular remodelling in the face of excessive cell proliferation, and to destroy invading cells such as leukocytes. 30 On the other hand, excessive apoptosis of existing glomerular cells will lead to progressive end-stage kidney failure. 30 Insulin is an important survival factor in mesangial cells, 31 and it is conceivable that insulin resistance in obesity may result in increased levels of apoptosis. The direct effects of leptin on apoptosis in mesangial cells is unknown; however, leptin has been shown to directly induce 14 or protect 15 a variety of cells from apoptosis. Here we investigated whether leptin directly altered apoptosis in mesangial cells. Under normal cell growth conditions or when elevated levels of apoptosis were stimulated by UV light, we found no direct effect of leptin on caspase-3-like activity. We also found that leptin did not alter DNA synthesis in mesangial cells. This is in agreement with observations reported previously, demonstrating that, while leptin acted as a mitogen for rat glomerular endothelial cells, no change in mesangial cell proliferation was observed. 13 As expected, since neither proliferation nor apoptosis was affected by leptin in our study, we found no change in the overall cell number when mesangial cells were grown in the presence of leptin. In summary, several studies have demonstrated that leptin can exert direct effects on kidney structure and function. 13, 21, 23, 24 We now show that leptin induces mesangial cell hypertrophy, but does not alter hyperplasia or apoptosis. These direct effects of leptin may play an important pathophysiological role in the development of kidney damage in obese individuals. Indeed, weight reduction, with a concomitant reduction in circulating leptin levels, is still a frontline therapy in the management of kidney disease in obese individuals. The potential importance of leptin, and other adipokines, in nephrology has recently begun to be appreciated, 11 and it is hoped that by understanding which adipokines regulate mesangial cell growth and viability we may develop strategies for attenuating mesangial cell hypertrophy as an effective therapy for treating obesityinduced kidney disease. Leptin induces mesangial cell hypertrophy MP-S Lee et al
